Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492160 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms
A Phase 2 study, sponsored by Maimonides Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 348
- Enrollment target
NCT07492160 is a Phase 2 study that is actively recruiting participants, run by Maimonides Medical Center. The registered enrollment target is 348 participants.
The verdict
NCT07492160, a Phase 2 study, is actively recruiting participants, sponsored by Maimonides Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 348 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are: Does cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss? Does cabergoline reduce the severity of breast symptoms and associated bother compared with placebo? Researchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss. Participants will: Complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure Receive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure Complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother A subset of participants will provide blood samples at selected time points to measure serum prolactin levels
Interventions
- DRUG Placebo
- DRUG Cabergoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07492160
The ClinicalTrials.gov registry entry for NCT07492160 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07492160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07492160 about?
NCT07492160 is a clinical study titled "Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms". The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are: Does cabergoline decrease ...
What is the current status of trial NCT07492160?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 348 participants. The study started on 2026-03-16. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07492160?
The interventions under investigation include: Placebo (DRUG), Cabergoline (DRUG).
Who is sponsoring clinical trial NCT07492160?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.